Site icon Duncan Bucknell

Pharma & Biotech Global Week in Review 27 Mar 09 from IP Think Tank

Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

 
Highlights this week included:

EU: ‘Inappropriate and misleading’: whatever happened to the original EPO response?; no skulduggery involved in pharma enquiry submission switch says EPO (IPKat) (IAM)

Superior Court of Justice reviews date from which TRIPS came into effect – Patent term cutbacks in Brazil and pharmaceutical pipelines (IP Think Tank) (IP Think Tank) (IP tango)

Harmonisation in Denmark: Patents covering pharmaceutical compositions may now be designated as basic patents (The SPC Blog)

 
General

GSK reports on corporate responsibility activities 2008/9 including commitment to cut price to patented medicines for poor countries (Intellectual Property Watch)

Debate between Patent Docs and author of Nature article ‘The dangers of diagnostic monopolies’ (Patent Docs) (Patent Docs)

Agricultural technology could feed rising population, but who will own crops? (Intellectual Property Watch)

Two final thoughts on big pharma acquisitions (IP finance)

Brazil: Patent term cutbacks in Brazil and pharmaceutical pipelines – IP Think Tank podcast 23 March 2009 (IP Think Tank)

Brazil: Patent term cutbacks – Lobbying, intellectual property and superior courts (IP Think Tank)

Brazil: Patent term extension (PTE) under TRIPs revisited and reviewed by Superior Court of Justice (IP tango)

Denmark: Harmonisation in Denmark: Patents covering pharmaceutical compositions may now be designated as basic patents (The SPC Blog)

Egypt: Boom time ahead for Egyptian generics? (Afro-IP)

EU: ‘Inappropriate and misleading’: whatever happened to the original EPO response?; no skulduggery involved in pharma enquiry submission switch says EPO (IPKat) (IAM)

India: Public sector IP and socially responsible licensing (Spicy IP)

India: Pharma lobby wants a probe into delayed orders (Spicy IP)

UK: Euro costs in UK litigation: Actavis UK Ltd v Novartis AG (PatLit)

US: Two biosimilars bills introduced in the House: HR 1427, the Promoting Innovation and Access to Life Saving Medicine Act; and H.R. 1548, the Pathway to BioSimilars Act (California Biotech Law Blog) (Managing Intellectual Property)

 
Products

Cubicin (Daptomycin) – US: Cubist files patent infringement suit against Teva over generic Cubicin ANDA (Law360) (The IP Factor) (GenericsWeb)

Cydectin (Moxidectin) – US: District Court Columbia grants FDA’s motion to dismiss/ summary judgment in Cydectin PTE case; rules that FDA rightly decided that the PTE review phase began upon submission of the Cydectin administrative NADA (FDA Law Blog) (Law360)

Fosamax (Alendronate) – EU: Opposition Division finds Merck’s patent relating to 70mg weekly Alendronate lacks inventive step (IPKat)

Fosrenol (Lanthanum carbonate) – US: Shire files lawsuit against Mylan for infringement of Fosrenol patent (SmartBrief) (SmartBrief) (GenericsWeb)

Keppra (Levetiracetam) – US: FTC declines to challenge reverse payment deal between Mylan, Dr Reddy’s and Cobalt on one side and UCB on the other (Law360) (Patent Docs)

Levaquin (Levofloxacin) – US: Daiichi Sankyo files patent infringement actions against 13 generic companies over Levofloxacin (GenericsWeb)

Lovaza (Omega 3) – US: Pronova BioPharma receives Lovaza para IV notice letter from Par Pharmaceutical (GenericsWeb)

Lunesta (Eszopiclone) – US: Sepracor lodges patent infringement suit against Teva, Dr Reddy’s, Mylan, Alphapharm over plans to make generic Lunesta (Law360) (GenericsWeb)

Neurontin (Gabapentin) – Vista, others drop claims in class action against Pfizer accusing it of scheme to delay generic competition for Neurontin (Law360)

Prilosec (Omeprazole) – US: District Court S D New York rules Dr Reddy’s ANDA for Omeprazole did not infringe Astra Zeneca’s patent (Spicy IP)

Primacare One – US: KV Pharmaceutical set to pull Primacare One prenatal vitamin supplement from the market; Lannett ends quest to invalidate KV’s patents (Law360)

Profender (Emodepside/Praziquantel) – UK: IPO follows Takeda in decision on SPC application on combination product: Astellas Pharma Inc’s application (The SPC Blog)

Risperdal (Resperidone) – US: Supreme Court denies Apote&xrsquo; appeal in Risperdal patent fight with Janssen Pharmaceutica (Law360) (Patent Docs)

Solodyn (Minocycline) – US: Teva, Medicis Pharma settle Solodyn patent dispute (Patent Docs)

Tarceva (Erlotinib) – US: OSI sues Teva, Mylan to block generic Tarceva (Law360) (SmartBrief)

 

 

Exit mobile version